Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13736606 | 0.77 | PIK3CD (0.54) | PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL691175 | 0.76 | ALDH1A1 (0.55) | PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL9964551 | 0.72 | ALDH1A1 (0.56) | PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL12680625 | 0.70 | ALDH1A1 (0.63) | PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL20614074 | 0.68 | CNR1 (0.31) | — | |
| SCHEMBL1176987 | 0.67 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL10502127 | 0.67 | HPGD (0.45) | PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL691848 | 0.66 | HPGD (0.44) | PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL17031863 | 0.66 | ATAD2 (0.36) | ALDH1A1GRM5 | |
| SCHEMBL13526463 | 0.64 | PDK1 (0.58) | ALDH1A1MAPTKDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273772-B2 | Heteroaryl compounds as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-25 | — | — | US | disclosed |
| US-20100093689-A1 | HETEROARYL COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-15 | — | — | US | disclosed |
| US-7645778-B2 | Heteroaryl compounds as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093689-A1 | HETEROARYL COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS | P2RY1, P2RY11, P2RY2 | PIK3CD 124/4885PIK3CA 97/4885PIK3CB 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.